Profile data is unavailable for this security.
About the company
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
- Revenue in USD (TTM)10.00m
- Net income in USD-113.63m
- Incorporated2017
- Employees109.00
- LocationJanux Therapeutics Inc10955 Vista Sorrento Parkway, Suite 200SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 751-4493
- Fax+1 (302) 655-5049
- Websitehttps://www.januxrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evommune Inc | 3.00m | -66.26m | 790.94m | 45.00 | -- | -- | -- | 263.65 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 791.09m | -- | 49.55 | 1.23 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 808.21m | 119.00 | 11.85 | 7.33 | 27.59 | 7.11 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Omeros Corp | 0.00 | -121.24m | 814.65m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 814.90m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Xencor Inc | 125.58m | -91.92m | 818.46m | 260.00 | -- | 1.26 | -- | 6.52 | -1.24 | -1.24 | 1.69 | 8.84 | 0.1374 | -- | 2.79 | 482,984.60 | -10.08 | -9.90 | -11.18 | -10.89 | -- | -- | -73.37 | -51.10 | -- | -- | 0.1585 | -- | 13.65 | 0.4654 | 60.48 | -- | -25.55 | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 819.36m | 270.00 | -- | 48.20 | -- | 54.20 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| Janux Therapeutics Inc | 10.00m | -113.63m | 849.82m | 109.00 | -- | 0.8816 | -- | 84.98 | -1.83 | -1.83 | 0.1614 | 15.85 | 0.0097 | -- | -- | 91,743.12 | -11.02 | -12.49 | -11.25 | -12.85 | -- | -- | -1,136.25 | -822.69 | -- | -- | 0.00 | -- | -5.55 | -- | -64.69 | -- | -- | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 850.81m | 62.00 | -- | 2.63 | -- | 143.79 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| MannKind Corp | 348.97m | 6.70m | 871.92m | 592.00 | 146.56 | -- | 45.94 | 2.50 | 0.0193 | 0.0193 | 1.12 | -0.1658 | 0.5885 | 2.45 | 6.56 | 589,469.60 | 1.13 | -7.58 | 1.44 | -9.71 | 77.80 | 70.19 | 1.92 | -14.56 | 1.50 | 1.31 | 1.09 | -- | 22.23 | 39.89 | -78.75 | -- | -0.9285 | -- |
| Arvinas Inc | 262.60m | -80.80m | 877.54m | 246.00 | -- | 2.01 | -- | 3.34 | -1.22 | -1.22 | 3.70 | 6.83 | 0.2903 | -- | 78.39 | 1,067,480.00 | -8.93 | -18.57 | -11.25 | -22.95 | -- | -- | -30.77 | -141.50 | -- | -- | 0.0009 | -- | -0.3037 | 64.50 | 59.38 | -- | -21.68 | -- |
| Personalis Inc | 69.65m | -81.27m | 895.65m | 260.00 | -- | 3.36 | -- | 12.86 | -0.9088 | -0.9088 | 0.7805 | 2.55 | 0.2305 | 8.92 | 5.72 | 267,876.90 | -26.89 | -30.49 | -30.46 | -34.81 | 22.65 | 27.97 | -116.69 | -118.80 | 6.61 | -- | 0.0197 | -- | -17.69 | -2.40 | 0.0172 | -- | 6.77 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 899.09m | 15.00 | -- | 14.47 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 901.50m | 162.00 | -- | 6.11 | -- | 6.31 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 903.92m | 44.00 | -- | 11.66 | -- | 61.89 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Geron Corp | 183.88m | -83.50m | 909.57m | 258.00 | -- | 4.02 | -- | 4.95 | -0.1252 | -0.1252 | 0.2758 | 0.353 | 0.3159 | 0.0611 | 5.04 | 712,717.10 | -14.34 | -38.37 | -17.32 | -48.79 | 97.42 | -- | -45.41 | -266.14 | 3.62 | -3.55 | 0.5245 | -- | 138.83 | 273.49 | 52.17 | -- | -34.32 | -- |
Data as of Mar 05 2026. Currency figures normalised to Janux Therapeutics Inc's reporting currency: US Dollar USD
59.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 11.19m | 18.62% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 5.25m | 8.73% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.85m | 6.41% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.44m | 5.71% |
| Prosight Management LPas of 03 Feb 2026 | 3.15m | 5.24% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.55m | 4.24% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 2.33m | 3.87% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 1.51m | 2.51% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 1.30m | 2.16% |
| FIAM LLCas of 31 Dec 2025 | 1.18m | 1.97% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
